central nervous system
The funds will be used to increase the development of GAIA-based Alzheimer's disease drugs and widen the pipeline of blockbuster drug candidates.
The company will use the funds to grow its team, expedite commercial deployments with pharma companies and enhance Willis, its new clinical outcome assessment platform.